Genmab 提议大幅减少股本，通过注销 treasury 股票。

summarizeSummary

Genmab A/S has announced its Annual General Meeting, where a key proposal includes a substantial reduction in share capital. The company plans to cancel 1,900,000 treasury shares, which were repurchased for approximately DKK 2.47 billion (around $359 million USD). This action is a positive move for shareholders as it reduces the number of outstanding shares, thereby enhancing earnings per share and overall shareholder value. Other agenda items, such as the adoption of the 2025 Annual Report and the re-election of board members and auditors, are routine corporate governance matters following the comprehensive 20-F filing on February 17, 2026.

check_boxKey Events

• 拟议减少股份资本

  Genmab A/S 提议Decrease其股本，通过取消1,900,000股自有股份，制止了2,473,734,807.58丹麦克朗（约359,000,000美元）用于收购这些股份。这个行动预计会通过减少总股本来增强股东价值。

• 年度股东大会召开

  公司将于2026年3月19日星期四举行年度股东大会，讨论各种公司治理问题，包括审计年度报告2025的通过和董事会成员和审计师的再次选举。

• 利润预留

  2025 年会计年度的利润 9630 万美元，建议将其转入盈余公积，而不是分配作股利。

auto_awesomeAnalysis

Genmab A/S has announced its Annual General Meeting, where a key proposal includes a substantial reduction in share capital. The company plans to cancel 1,900,000 treasury shares, which were repurchased for approximately DKK 2.47 billion (around $359 million USD). This action is a positive move for shareholders as it reduces the number of outstanding shares, thereby enhancing earnings per share and overall shareholder value. Other agenda items, such as the adoption of the 2025 Annual Report and the re-election of board members and auditors, are routine corporate governance matters following the comprehensive 20-F filing on February 17, 2026.